Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study;FINASTERID VED SYMPTOMGIVENDE BENIGN PROSTATAHYPERTROFI. ET TOAARS PLACEBOKONTROLLERET STUDIE

Ugeskrift for Laeger

Volumn 158, Issue 36, 1996, Pages 5030-5035

  Andersen, Jens Thorup ^a   Wolf, Hans ^b   Ekman, Peter ^b   Beisland, Hans Olav ^b   Johansson, Jan Erik ^b   Kontturi, Matti ^b   Lehtonen, Timo ^b   Tveter, Kjell ^b  

^a HVIDOVRE HOSPITAL   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA;

EID: 0029785889     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Oesterling JE. Benign prostatic hyperpiasia: medical and minimally invasive treatment options. N Engl J Med 1995; 332: 99-109.
2. Lytton B, Emery JM, Harvard BM. The incidence of benign prostatic obstruction. J Urol 1968; 99: 639-45.
3. Guess HA. Benign prostatic hyperplasia: antecedents and natural history. Epidemiol Rev 1992; 14: 131-53.
4. Scott WW. What makes prostate grow? J Urol 1953; 70: 477-88.
5. Andersen JT. Prostatism, clinical, urodynamic and radiological aspects. Neurol Urodyn 1982; 1: 241-93.
6. Blandy JP, Lytton B, eds. The prostate. London: Butterworths, 1986.
7. Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. N Engl J Med 1995; 332: 75-9.
8. Bruchovsky N, Wilson JD. The conversion of testosterone to 5alpha-androstane-17beta-oI-3 one by rat prostate in vivo and in vitro. J Biol Chem 1968; 243: 2012-21.
9. Stoner E. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 1994; 43: 284-94.
10. Beisland HO, Binkowitz B, Brekkan E, Ekman P, Kontturi M, Lehtonen T et al. Scandinavian clinical study of finassteride in the treatment of benign prostatic hyperplasia. Eur Urol 1992; 22: 271-7.
11. Gormley GJ, Stoner E, Bruskewitz RD, Imperato-McGinley J, Walsh PC, McConnell JD et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992; 327: 1185-91.
12. Finasteride Study Group, Stoner E. Finasteride (MK-906). in the treatment of benign prostatic hyperplasia. Prostate 1993; 22: 291-9.
13. Ekman P. Efficacy of placebo in the treatment of benign prostatic hyperplasia. I: Puppo P, ed. Contemporary BPH Management Bologna: Mundez Editore, 1993: 35-41.
14. Boyarsky S, Jones G, Paulson DF, Prout GR Jr. A new look at bladder neck obstruction by the Food and Drug Administration regulators: guide lines for investigation of benign prostatic hypertrophy. Trans Am Assoc Genitorourin Surg 1976; 68: 29-32.
15. Bolognese JA, Kozloff RC, Kunik SC, Grino PB, Patrick DL, Stoner E. Validation of a symptoms questionnaire for benign prostatic hyperplasia. Prostate 1992; 21: 247-54.
16. Grino PB, Bruskewitz RC, Blaivas JG, Siroky MB, Andersen JT, Cook T et al. Maximum urinary flow rate by uroflowmetry: automatic or visual interpretation. J Urol 1993; 149: 339-41.
17. Coombes GM, Millard RJ. Accuracy of portable ultrasound skanning in the measurement of residual urine volume. J Urol 1994; 152: 2083-5.
18. Girman CJ, Jacobsen SJ, Guess HA, Oesterling JE, Chute CG, Panser LS et al. Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate. J Urol 1995; 153: 1510-5.
19. Benign Prostatic Hyperplasia Guideline Panel. Benign prostatic hyperplasia: diagnosis and treatment Washington. DC: US Government Printing Office, 1994: 73-5.